Conclusions Systematic identification of new-onset arrhythmias following TAVI may have considerable impact on subsequent therapeutic management and long-term prognosis in this patient population
Objective To evaluate the prevalence and clinical impact of new-onset arrhythmias in patients following transcatheter aortic valve implantation ( TAVI ) .
Outcomes after transfemoral transcatheter aortic valve replacement: a comparison of the randomized PARTNER (Placement of AoRTic TraNscathetER Valves) trial with the NRCA (Nonrandomized Continued Access) registry.
OBJECTIVES This study sought to determine whether outcomes for transfemoral ( TF ) transcatheter aortic valve replacement ( TAVR )  differ between the r and omized controlled trial ( RCT ) and the subsequent NRCA ( Nonr and omized Continued Access ) registry of the PARTNER ( Placement of AoRTic TraNscathetER Valves ) trial . BACKGROUND The PARTNER RCT demonstrated that TAVR with the Edwards Sapien valve ( Edwards Lifesciences , Irvine , California ) is noninferior to surgery in high-risk patients and superior to st and ard therapy for inoperable patients . METHODS The inclusion and exclusion criteria , data collection , monitoring , and core laboratories were the same for the RCT and NRCA registry . Baseline characteristics , procedural results , and 1-year outcomes were compared between patients undergoing TF-TAVR  as part of the RCT and as part of the NRCA registry . RESULTS In the RCT , 415 patients underwent TF-TAVR , whereas in the NRCA , 1,023 patients did . At 30 days , death , cardiac death , stroke , and transient ischemic attacks were not different in the NRCA registry than in the RCT . Major vascular complications ( 8.0 % vs. 15.7 % , p < 0.0001 ) and major bleeding ( 6.8 % vs. 15.3 % , p < 0.0001 ) were significantly lower in the NRCA registry . At 1 year , death rates were significantly lower in the NRCA cohort ( 19.0 % vs. 25.3 % , p = 0.009 ) and cardiac death tended to be lower ( 8.4 % vs. 11.1 % , p = 0.12 ) . Stroke or transient ischemic attack ( 6.2 % vs. 8.7 % , p = 0.10 ) and stroke alone ( 5.0 % vs. 7.1 % , p = 0.13 ) also tended to be lower . CONCLUSIONS The large NRCA registry demonstrates further improvement in procedural and longer-term outcomes after TF-TAVR when compared with the favorable results from the PARTNER RCT . ( THE PARTNER TRIAL : Placement of AoRTic TraNscathetER Valve Trial ; NCT00530894 )
Conclusions Systematic identification of new-onset arrhythmias following TAVI may have considerable impact on subsequent therapeutic management and long-term prognosis in this patient population
Objective To evaluate the prevalence and clinical impact of new-onset arrhythmias in patients following transcatheter aortic valve implantation ( TAVI ) .